Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market

Show simple item record

dc.contributor.author Corcoran, Paul
dc.contributor.author Reulbach, Udo
dc.contributor.author Keeley, Helen S.
dc.contributor.author Perry, Ivan J.
dc.contributor.author Hawton, Keith
dc.contributor.author Arensman, Ella
dc.date.accessioned 2016-06-15T14:24:57Z
dc.date.available 2016-06-15T14:24:57Z
dc.date.issued 2010-03-18
dc.identifier.citation Corcoran, P., Reulbach, U., Keeley, H. S., Perry, I. J., Hawton, K. and Arensman, E. (2010) 'Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market'. BMC Clinical Pharmacology, 10, 6. http://dx.doi.org/10.1186/1472-6904-10-6 en
dc.identifier.volume 10 en
dc.identifier.startpage 6(1) en
dc.identifier.endpage 6(8) en
dc.identifier.issn 1472-6904
dc.identifier.uri http://hdl.handle.net/10468/2744
dc.identifier.doi 10.1186/1472-6904-10-6
dc.description.abstract BACKGROUND: Distalgesic, the prescription-only analgesic compound of paracetamol (325 mg) and dextropropoxyphene (32.5 mg) known as co-proxamol in the UK, was withdrawn from the Irish market as of January 2006. This study aimed to evaluate the impact of the withdrawal of distalgesic in terms of intentional drug overdose (IDO) presentations to hospital emergency departments (EDs) nationally. METHODS: A total of 42,849 IDO presentations to 37 of the 40 hospitals EDs operating in Ireland in 2003-2008 were recorded according to standardised procedures. Data on sales of paracetamol-containing drugs to retail pharmacies for the period 1998-2008 were obtained from IMS Health. RESULTS: The withdrawal of distalgesic from the Irish market resulted in an immediate reduction in sales to retail pharmacies from 40 million tablets in 2005 to 500,000 tablets in 2006 while there was a 48% increase in sales of other prescription compound analgesics. The rate of IDO presentations to hospital involving distalgesic in 2006- 2008 was 84% lower than in the three years before it was withdrawn (10.0 per 100,000). There was a 44% increase in the rate of IDO presentations involving other prescription compound analgesics but the magnitude of this rate increase was five times smaller than the magnitude of the decrease in distalgesic-related IDO presentations. There was a decreasing trend in the rate of presentations involving any paracetamol-containing drug that began in the years before the distalgesic withdrawal. CONCLUSIONS: The withdrawal of distalgesic has had positive benefits in terms of IDO presentations to hospital in Ireland and provides evidence supporting the restriction of availability of means as a prevention strategy for suicidal behaviour. en
dc.description.sponsorship Health Service Executive, Ireland (HSE National Office for Suicide Prevention); Medical and Healthcare products Regulatory Agency, UK (MHRA) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher BioMed Central en
dc.rights © 2010 Corcoran et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.rights.uri http://creativecommons.org/licenses/by/2.0 en
dc.subject Analgesic agent en
dc.subject Paracetamol en
dc.subject Intentional drug overdose (IDO) en
dc.subject Distalgesic en
dc.subject Co-proxamol en
dc.subject Drug legislation en
dc.subject Suicide en
dc.subject Suicide attempt en
dc.title Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Paul Corcoran, Epidemiology & Public Health, University College Cork, Cork, Ireland. +353-21-490-3000 Email: pcorcoran@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2014-10-29T12:14:56Z
dc.description.version Published Version en
dc.internal.rssid 229124167
dc.contributor.funder Medical and Healthcare products Regulatory Agency (MRHA), UK en
dc.contributor.funder Health Service Executive, Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle BMC Clinical Pharmacology en
dc.internal.copyrightchecked Yes !!CORA!! en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress pcorcoran@ucc.ie en
dc.identifier.articleid 6


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2010 Corcoran et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Except where otherwise noted, this item's license is described as © 2010 Corcoran et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement